Shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) have been given a consensus recommendation of “Hold” by the twenty-three analysts that are covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a sell recommendation, fourteen have assigned a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $16.96.

A number of equities analysts have recently weighed in on the company. Jefferies Group LLC set a $18.00 price objective on Valeant Pharmaceuticals International and gave the stock a “buy” rating in a research note on Saturday, May 6th. Piper Jaffray Companies set a $14.00 price target on Valeant Pharmaceuticals International and gave the company a “sell” rating in a research note on Wednesday, August 9th. HC Wainwright set a $17.00 price target on Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Wednesday, August 9th. Canaccord Genuity set a $14.00 price target on Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Thursday, August 10th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $35.00 price target on shares of Valeant Pharmaceuticals International in a research note on Thursday, August 10th.

Several large investors have recently modified their holdings of VRX. Dimensional Fund Advisors LP increased its stake in shares of Valeant Pharmaceuticals International by 86.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 576,634 shares of the specialty pharmaceutical company’s stock valued at $8,372,000 after buying an additional 268,116 shares during the last quarter. Guggenheim Capital LLC increased its stake in shares of Valeant Pharmaceuticals International by 18.6% in the fourth quarter. Guggenheim Capital LLC now owns 17,540 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 2,752 shares during the last quarter. Gulf International Bank UK Ltd increased its stake in shares of Valeant Pharmaceuticals International by 1.1% in the first quarter. Gulf International Bank UK Ltd now owns 98,323 shares of the specialty pharmaceutical company’s stock valued at $1,084,000 after buying an additional 1,100 shares during the last quarter. Capstone Asset Management Co. increased its stake in shares of Valeant Pharmaceuticals International by 13.6% in the first quarter. Capstone Asset Management Co. now owns 32,988 shares of the specialty pharmaceutical company’s stock valued at $364,000 after buying an additional 3,940 shares during the last quarter. Finally, Columbus Circle Investors increased its stake in shares of Valeant Pharmaceuticals International by 24.6% in the first quarter. Columbus Circle Investors now owns 75,252 shares of the specialty pharmaceutical company’s stock valued at $830,000 after buying an additional 14,880 shares during the last quarter. Hedge funds and other institutional investors own 50.96% of the company’s stock.

Shares of Valeant Pharmaceuticals International (NYSE VRX) opened at 14.34 on Friday. The company’s market cap is $5.00 billion. The stock’s 50 day moving average price is $16.27 and its 200-day moving average price is $13.39. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $32.74.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.97 by $0.08. The firm had revenue of $2.23 billion during the quarter, compared to analyst estimates of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The business’s quarterly revenue was down 7.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.88) earnings per share. Equities research analysts expect that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/08/18/valeant-pharmaceuticals-international-inc-vrx-receives-average-recommendation-of-hold-from-brokerages.html.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.